PMID: 2498964Jan 1, 1989Paper

Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization

Psychopharmacology
H UjikeS Otsuki

Abstract

The present study examined effects of selective antagonists of D-1 and D-2 dopamine receptors on the development of behavioral sensitization produced by repeated methamphetamine (MAP) administration. Male Sprague-Dawley rats were divided into four groups. Each group received a daily injection of saline (control group), 4 mg/kg MAP (MAP group), 1 mg/kg YM-09151-2 plus 4 mg/kg MAP (YM + MAP group) or 0.5 mg/kg SCH 23390 plus 4 mg/kg MAP (SCH + MAP group) for 14 days. During daily injection for 14 days, the MAP group exhibited a progressive augmentation in locomotor and stereotyped behavior, whereas the progression of such behaviors in the YM + MAP and SCH + MAP group was completely prevented. After an abstinence period of 7 days, all groups received a challenge of 2 mg/kg MAP. The MAP challenge reproduced hyperlocomotion and intense stereotyped behavior only in the MAP group. However, neither the YM + MAP group nor the SCH + MAP group showed stereotypy. The manner in which both groups showed only hyperlocomotion was similar to that observed in the control group. These results indicate that both selective D-1 antagonists and selective D-2 antagonists not only reverse MAP-induced motor effects at each injection but also prevent the...Continue Reading

References

Apr 29, 1977·Psychopharmacology·L ShusterA Bates
Dec 1, 1978·Neuropharmacology·L R Nelson, G Ellison
Feb 12, 1985·European Journal of Pharmacology·I Creese, A Chen
Jun 1, 1985·Naunyn-Schmiedeberg's Archives of Pharmacology·H B NiznikP Seeman
Dec 3, 1985·European Journal of Pharmacology·M L PorcedduG Biggio
Oct 1, 1973·The American Journal of Psychiatry·E H EllinwoodL M Nelson
Jul 1, 1974·The American Journal of Psychiatry·B AngristS Gershon
Mar 1, 1974·Pharmacology, Biochemistry, and Behavior·D S Segal, A J Mandell
Jun 20, 1968·The New England Journal of Medicine·D E Espelin, A K Done
Aug 1, 1983·Japanese Journal of Pharmacology·M TeraiH Maeno
Jul 15, 1983·European Journal of Pharmacology·J Hyttel
May 18, 1984·European Journal of Pharmacology·R B MailmanD L Dehaven
Oct 30, 1984·European Journal of Pharmacology·D W SchulzR B Mailman

❮ Previous
Next ❯

Citations

May 16, 2009·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Xiangqian LiuSulie L Chang
Jul 6, 2011·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Kathleen M GrantRick A Bevins
May 11, 2002·Current Psychiatry Reports·Hiroshi Ujike
Jan 25, 1996·European Journal of Pharmacology·H UjikeS Otsuki
Apr 1, 1995·Pharmacology, Biochemistry, and Behavior·H UjikeS Kuroda
Jan 1, 1994·Pharmacology, Biochemistry, and Behavior·K TsuchidaK Akiyama
Jan 1, 1994·Neuroscience and Biobehavioral Reviews·J M Witkin
Jan 1, 1992·Neurotoxicology and Teratology·F M Scalzo, R R Holson
Jun 18, 2002·European Journal of Pharmacology·Charles W SchindlerEric B Thorndike
Feb 26, 2003·European Journal of Pharmacology·Kiyoyuki KitaichiTakaaki Hasegawa
Sep 22, 2001·Neuroscience and Biobehavioral Reviews·N M RichtandS M Strakowski
Dec 24, 1997·Behavioural Brain Research·P H JanakJ L Martinez
Jan 7, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·V VõikarE Vasar
Oct 26, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jean-Christophe CorvolDenis Hervé
Nov 21, 1998·The European Journal of Neuroscience·T HashimotoT Nishikawa

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.